|Over a week ago|
Caladrius files to sell 2.12M shares of common stock for holders 16:0406/1906/19/20
|Over a month ago|
Caladrius closes $4.3M registered direct offering priced at-the-market » 13:3605/2805/28/20
Caladrius Biosciences announced that it has closed on its previously announced sale of an aggregate of 2,084,850 shares of its common stock to several institutional and accredited investors, at a purchase price of $2.0625 per share, in a registered direct offering priced at-the-market under Nasdaq rules. Under the purchase agreement, Caladrius has also issued to the investors unregistered warrants to purchase up to an aggregate of 1,042,425 shares of common stock. H.C. Wainwright & Co. acted as the exclusive lead placement agent for the offering. Brookline Capital Markets, a division of Arcadia Securities, LLC, acted as co-placement agent for the offering. The warrants have an exercise price equal to $2.0625 per share, are exercisable immediately upon issuance and will expire five and one-half years from the issuance date. The gross proceeds from the offering were approximately $4.3M. The company currently intends to use the net proceeds from the offering for working capital and general corporate purposes, including the advancement of its CD34+ technology-based clinical programs.
Caladrius announces $4.3M registered direct offering priced at-the-market » 08:2405/2605/26/20
Caladrius Biosciences announced that it has entered into definitive agreements with several institutional and accredited investors for the issuance and sale of an aggregate of 2,084,850 shares of its common stock, at a purchase price of $2.0625 per share, in a registered direct offering priced at-the-market under Nasdaq rules. Caladrius has also agreed to issue to the investors unregistered warrants to purchase up to an aggregate of 1,042,425 shares of common stock. The closing of the offering is expected to occur on or about May 28, 2020, subject to the satisfaction of customary closing conditions. H.C. Wainwright & Co. is acting as the exclusive lead placement agent for the offering. The warrants have an exercise price equal to $2.0625 per share, are exercisable immediately upon issuance and will expire five and one-half years from the issuance date. The gross proceeds from the offering are expected to be approximately $4.3M. The company currently intends to use the net proceeds from the offering for working capital and general corporate purposes, including the advancement of its CD34+ technology-based clinical programs.
Caladrius initiated with a Buy at Brookline » 10:2105/2205/22/20
Brookline analyst Kumaraguru Raja initiated coverage of Caladrius Biosciences with a Buy rating and $7 price target.
Caladrius downgraded to Neutral from Buy at Dawson James » 07:2105/1805/18/20
Dawson James analyst…
Dawson James analyst Jason Kolbert downgraded Caladrius to Neutral from Buy.
Caladrius reports 'positive' results for CLBS16 from ESCaPE-CMD trial » 15:4405/1405/14/20
Caladrius Biosciences presented full data results from the ESCaPE-CMD trial of Caladrius's autologous CD34+ cell therapy, CLBS16, at the Society for Cardiovascular Angiography and Interventions 2020 Scientific Sessions Virtual Conference. Data showed highly statistically significant improvement in coronary flow reserve correlating with symptom relief for patients with coronary microvascular dysfunction after a single intracoronary injection of CLBS16. "We are extremely pleased, yet not surprised, that the full results for the ESCaPE-CMD corroborate the previously reported and very positive partial data from the study," said Douglas Losordo, M.D., FACC, FAHA, Chief Medical Officer at Caladrius. "The results show an encouraging ability to increase CFR and potentially reverse CMD, a disease that disproportionately afflicts more women than men, after a single administration. The outcome from this study brings us one step closer to realizing the promise of CD34+ cell therapy to augment microvasculature in the heart enabling the restoration of health rather than simply management of disease. We look forward to initiating the next trial for this program, a Phase 2b study, in the fall of 2020."
Caladrius reports Q1 EPS (38c) versus (44c) in Q1 last year » 16:4605/0705/07/20
The Company's open-label, registration-eligible study of CLBS12, its SAKIGAKE-designated product candidate, in Japan for the treatment of critical limb ischemia ("CLI"), a disease with no currently available approved therapy6 and a higher mortality rate than all cancers except that of lung cancer,7 has shown positive results to date. The Buerger's Disease cohort has concluded with 4 out of 7 (57%) patients achieving a positive outcome. Although the study enrollment, which had been targeted for completion this year, has been slowed by the impact of the COVID-19 pandemic in Japan, the Company is encouraged by the patient pre-screening pipeline that has been identified and hopes to conclude the trial enrollment rapidly once the coronavirus abates and physicians are again able to treat non-COVID-19 patients. Based on the data from the concluded Buerger's Disease cohort and the data to date in the no-option CLI cohort, the Company affirms its expectation of the study's ultimate success
Caladrius to assess CLBS119 cell therapy for repair of COVID-19 lung damage » 09:0504/2304/23/20
Caladrius Biosciences announced that the U.S. Food and Drug Administration has authorized its investigational new drug application for the study of CLBS119, a CD34+ cell therapy for repair of COVID-19 induced lung damage. The study will target patients with severe SARS-CoV-2 infection that required ventilatory support due to respiratory failure.
Caladrius to receive $10.9M of non-dilutive capital through NJEDA tax program » 08:1704/2204/22/20
Caladrius Biosciences announced that it has finalized an agreement to sell $10.9M in New Jersey net operating losses to a qualifying and approved buyer pursuant to the New Jersey Economic Development Authority's Technology Business Tax Certificate Transfer Program. The Program enables qualifying New Jersey-based biotechnology or technology companies to sell a percentage of their NJ NOLs and research and development tax credits to unrelated qualifying corporations.
|Over a quarter ago|
Noble Capital to hold a conference » 07:5002/1802/18/20
UAVS, CLBS, CMTL, COCP, CPST, LCTX, XBIO, SPI, ESEA
16th Annual NobleCon…
16th Annual NobleCon Investor Conference will be held in Hollywood, FL on February 16-18.